Subscribe to Snippets

Skinny Labels and Inducement in Pharma Patent Litigation – “IP in 5” video series

In this episode of “IP in 5,” MBHB Partner Grantland Drutchas and Associate Taylor Weilnau discuss the role of drug labeling in pharma patent litigation and share thoughts on how to navigate the intersection of FDA regulation, patent law, and commercial strategy.

AI News Roundup – Trump administration readies executive order to block state AI regulations, Google unveils newest AI model, UAE and Saudi Arabia gain access to advanced Nvidia AI chips, and more

MBHB Partner Andrew Velzen on the role of public discourse in the USPTO director’s Pokémon decision

AI News Roundup – Anthropic’s Claude used to automate cyberattacks, OpenAI loses copyright case in German court, AI cheating scandal rocks South Korean universities, and more

About the Authors

Grantland G. Drutchas

Grantland G. Drutchas is a founder of MBHB and co-Chair of the firm's PTAB Trials Practice Group and Licensing Practice Group. He represents clients in intellectual property litigation, clearances, and opinions, and supports their patent licensing efforts by drafting licenses and litigating license disputes. Drawing on more than 25 years of experience in intellectual property law, he counsels clients on global patent portfolio strategies.

Taylor Weilnau

Taylor Weilnau supports life sciences clients in all phases of patent prosecution, portfolio management, and intellectual property strategy and litigation. Ms. Weilnau draws from her academic background in molecular biology and biochemistry, as well as her professional experience in medical academia, to provide clients comprehensive support on intellectual property matters involving molecular biology, genomics, biologics and biosimilars, diagnostic technologies, pharmaceutical biotechnology, and artificial intelligence in biotechnology.

© 2025 McDonnell Boehnen Hulbert & Berghoff LLP snippets is a trademark of McDonnell Boehnen Hulbert & Berghoff LLP. All rights reserved. The information contained in this newsletter reflects the understanding and opinions of the author(s) and is provided to you for informational purposes only. It is not intended to and does not represent legal advice. MBHB LLP does not intend to create an attorney–client relationship by providing this information to you. The information in this publication is not a substitute for obtaining legal advice from an attorney licensed in your particular state. snippets may be considered attorney advertising in some states.